We are Promatix Inc. of 78 Pall Mall, London, SW1Y 5ES, United Kingdom at https://www.pro-matix.com/, (“we” or “the Firm”) and we are subject to the laws of England and Wales. We use your information as further explained in this Privacy Notice. We will be the “controller” of the information you provide to us.
We collect basic personal data about potential and existing clients, investors and partners from time-to-time, such as names, email addresses and addresses.
We may, in addition to the above, collect your date and place of birth, telephone number, job title, tax identification number, photocopy of identification and sometimes proof of address.
We will not ask you to provide any sensitive information(such as health data) or use your information to build profiles about you.
Personal information and/or data may be used to:
All the personal data we process is processed by our staff in the United Kingdom to:
We may share your information with our service providers such as our IT service providers for the purposes of providing services to us, including data storage.
In addition to the uses outlined above, our staff in the UnitedKingdom may, if required, process your personal data to:
We may share your information with:
This information is located on servers within the United States of America for the purposes of IT hosting and maintenance.
No other third parties have access to your information unless we specifically say so in this Privacy Notice, or the law requires this.
If you have provided consent or we otherwise have the right to do so, we may, to the extent permissible by law, send to you direct marketing and promotional materials relating to our services or related products, for example sending you communications (including by email) for these purposes.
Where we rely on legitimate interest as a basis for processing your personal information, we carry out a ‘balancing test’ to ensure that our processing is necessary and that your fundamental rights of privacy are not outweighed by our legitimate interests. You can find out more information about these balancing tests by contacting us at enquiries@pro-matix.com.
We will hold your personal information only for as long as necessary to carry out the data processing purposes stated above, following which we will securely destroy your personal information. Your personal information will be kept securely to prevent unauthorised access by other people. You must inform us of any changes to your personal information so that we can keep it up to date. Should you notify us of such changes, we will notify any of the above-mentioned third parties (if we have disclosed your personal information to them) of these changes, to ensure your records are rectified and remain accurate.
You have the right to be provided with clear, transparent and easily understandable information about how we use your information and your rights. This is why we are providing you with the information in this Privacy Notice.
You have the right to access the information we hold about you. We usually act on requests and provide information free of charge but may charge a reasonable fee to cover our administrative costs of providing the information for requests which are manifestly unfounded or excessive.
You have the right to ask us (and third parties to whom we transfer your personal information) to rectify your personal information if it becomes inaccurate.
We need to notify any third parties with whom we have shared your information that you have made a rectification request (see “What do we do with it?” above) We will take reasonable steps to do this, but this may not always be possible or may involve disproportionate effort.
You have the right to ask us to erase your personal information if:
You have the right to restrict our processing of your personal information in certain circumstances. When processing is restricted, we may store your personal information, but may not use it further.
You have rights to obtain and reuse your personal data for your own purposes across different services in a structured, commonly used and machine-readable format in certain circumstances. In addition, where certain conditions apply, you have the right to have such information transferred to another party.
If the personal information concerns more than one individual, we may not be able to transfer this to you if doing so would prejudice that person’s rights.
You have the right to object to certain types of the processing of your personal data, in certain circumstances. In particular, you have the right to object to the processing of your personal data based on our legitimate interest or on public interest grounds, and the right to object to processing for direct marketing purposes (including profiling).
If you have provided your consent to the collection, processing and transfer of your personal information for a specific purpose, you have the right to withdraw your consent for that specific processing at any time. To withdraw your consent, please contact enquiries@pro-matix.com. Once we have received notification that you have withdrawn your consent, we will no longer process your information for the purpose(s) to which you originally consented unless required to retain your information for a legal or regulatory purpose.
If you have any questions, would like to talk to someone about this Privacy Notice, access your personal information or make a complaint about how we have handled your information, please contact enquiries@pro-matix.com.
If you believe our processing of your personal information does not comply with data protection law, you can make a compliant to theInformation Commissioner’s Office using the following details:
Information Commissioner’s Office
Wycliffe House
Water Lane
Wilmslow
Cheshire
SK9 5AF
United Kingdom
Tel: 0303 123 1113
www.ico.org.uk
You must NOT use this website (or permit or procure others to use it) as follows:
When using this website, you must comply with all applicable local, national and international laws and regulations, including those related to data privacy, international communications and exportation of technical or personal data. It may be illegal to download the information contained on this website in certain countries and Promatix Inc and its affiliated entities, persons and partners disclaim all responsibility if you download any information from this website in breach of any law or regulation of the country in which you reside.
The entire contents of this website are subject to copyright with all rights reserved. The copyright, trademarks and all similar rights of this website and the contents, including all information, graphics, code, text and design, are owned by Promatix Inc (or its licensors).
You may download or print individual sections of this website for your personal use and information only provided that you ensure that all copyright notices and other proprietary notices are displayed on such downloaded or printed sections. You may not reproduce (in whole or in part),transmit (by electronic means or otherwise), modify, link into or use for any public or commercial purpose this website without the prior written permission of Promatix Inc.
Nothing on this website should be construed as granting any licence or right in relation to any of the trademarks of Promatix Inc or those of its affiliated entities, persons and partners or any third party.
This website, including information and materials contained in this website, text, graphics, software, links and other items (collectively, the “Website Content”) are provided in good faith “as is” and “as available” basis for information purposes only with no representation or warranty, express or implied byPromatix Inc or by any of its members, shareholders, partners, directors, officers, employees, managers, executives, representatives, agents or advisers as to the accuracy adequacy, completeness, timeliness or availability of such Website Content, and it should not be relied on as such. Accordingly, Promatix Inc expressly disclaims liability for errors or omissions in this website. There is no warranty of merchantability, no warranty of fitness for a particular purpose, no warranty of non-infringement, no warranty of any kind, implied, express or statutory, in conjunction with this website.
To the extent permitted by laws and regulations, in no event will Promatix Inc, its members, shareholders, partners, directors, officers, employees, managers, executives, representatives, agents or advisers be liable whether in tort (including negligence) or otherwise howsoever, for any damages, including, without limitation, direct or indirect, special, incidental or consequential damages, unforeseeable loss or loss of bargain, opportunity or profit or other Losses (as defined below) of whatever nature arising or in connection with this website or the access to, or use or misuse thereof or reliance on any information contained on this website or the inability by any party to use this website, or in connection with any failure of performance, error, omission, interruption, defect, delay in operation or transmission, computer virus or line or system failure, even if Promatix Inc, or representatives thereof, are advised of the possibility of such Losses.
Promatix Inc will not be liable for any Losses caused by a distributed denial-of-service attack, virus, worm, trojan horse or other harmful material that may infect your computer equipment, computer programs, data or other proprietary material due to your use of this website or to your downloading of any material from it.
As a condition of your use of this website, you agree to indemnify and hold harmless Promatix Inc and its affiliates, and the members, shareholders, partners, directors, officers, employees, managers, executives, representatives, agents and advisers of Promatix Inc and its affiliates from and against any and all liabilities, actions, suits, costs, claims, damages, losses or expenses, including legal fees and expenses, (together, “Losses”)arising out of your access to or use of this website, save to the extent that Promatix Inc may not exclude or limit its own liability for such Losses pursuant to applicable laws or regulations.
This website is established in England by Promatix Inc in accordance with and shall be governed by, and your browsing in and use of this website shall be deemed acceptance of, the laws of England and Wales. A condition of using this website is that in the event of any dispute or proceeding you irrevocably submit to the exclusive jurisdiction of the EnglishCourts and waive any objection to proceedings in such courts on the grounds of venue or on the grounds that the proceedings have been brought in an inconvenient forum.
Promatix Inc may revise these Terms of Use at any time by amending this page. You are expected to check this page from time to time to take notice of any changes Promatix Inc makes, as they are binding on you.
Each time you use this website, a condition of use is that you comply with the above Terms of Use.
We are a UK-based startup developing new classes of cancer therapies using bispecific antibodies.
Our focus is on identifying new target combinations for cis-bispecific ADCs.
Driven by proteomic analysis of all membrane proteins - the surfaceome - in normal and cancer tissue from patients.
We are exemplifying our platform by developing a pipeline of novel bispecific ADCs in colorectal cancer (CRC).
We have a catalogue of bispecific assets with novel pairings tuned for fourteen common types of cancer identified using a combination of proprietary algorithms.
We use bispecific antibodies to improve tumour selectivity and therapeutic index by exploiting hybrid avidity.
The Promatix platform allows a systematic search for optimum combinations of cancer surface markers for cis-bispecific targeting of tumours - where both markers are present on the cancer cells.
This dramatically reduces on target off tumour toxicity…
... and has the potential to expand the range of targets and indications for ADCs (Antibody Drug Conjugates).
TxPro
CipherPro
AviPro
BiPro
Alek has a diverse background in drug development spanning more than thirty years. Trained as a pharmacist, he worked in regulatory affairs and clinical research roles for European and US-based multinational pharmaceutical companies in Australia, with responsibility across the Asia-Pacific. He subsequently founded Novotech, a Sydney-based contract research organisation working with hundreds of clinical stage biotech companies over a twenty-one year period. Alek holds a BPharm and an MBA from the University of Sydney.
Chairman
Robert has a successful background in venture capital and Big Pharma, with companies such as GSK and Eli Lilly. He is a passionate start-up entrepeneur with experience in university technology transfer. Robert holds a BSc in Physiology and a PhD in Neurophysiology.
Director
Lorna has more than twenty years of experience in private equity and venture capital with roles at EQT, Hermes GPE, Citco, Coller Capital, Ariadne Capital, Actis and BancBoston Capital. She holds a BA in Applied Psychology and is registered with the Chartered Institute of Management Accountants (ACMA).
CFO
Mick has over 40 years biotech experience spanning concept to clinic for multiple IND candidates across a range of therapeutic indications including management of process development and GMP biologics production. He has held senior R&D executive positions at GD Searle, Atopix, Oxagen, British Biotech. He was the CSO of Atopix, sold to Chiesi in 2016, and founder and CEO of Orca Pharmaceuticals, whose ROR gamma program was licensed to AstraZeneca and to Brickell Biotech. More recently Mick was Entrepreneur in Residence at Evotec. He holds a PhD in Molecular Biology and Genetics from the University of Nottingham.
CEO
Mark has a 40 year background in applying protein engineering to drug discovery and development and is now a free-lance consultant providing advice to life-science start-up companies. He has previously held positions at Searle, PA Technology, British Biotech and was the founding Director at Oxagen. He holds a BA in Biochemistry and DPhil in bacterial gene expression from Oxford.
CTO
Roy has over 30 years of industry experience in anti-inflammatory and oncology drug discovery and development. He is the founder and CSO at Orca Pharmaceuticals, a program licensed to AstraZeneca and has previously served as the research director at Atopix, which was sold to Chiesi in in 2016. He has also held senior R&D executive positions in biotech (Oxagen & AdoRx)and Pharma(Pfizer & Wellcome). Roy holds a PhD in Pharmacology from the University of London.
CSO
Shan has over 20 years biotech experience in drug discovery and development. She has previously held project management positions at Atopix and Oxagen where she gained extensive experience in the management of outsourced preclinical and clinical development studies, documentation, project planning and budgeting. Shan holds a BSc in Biochemistry and a PhD in Intracellular signalling.
Project Manager
Katherine is a proven leader in biologics discovery, with 25 years experience across biotech, biopharm and service organisations where she has built an extensive portfolio of candidate biologics in multiple disease areas. She has had significant strategic, project and group leadership roles at MedImmune/ AstraZeneca, Charles River and most recently held the position of site lead for AbCellera's UK-based laboratory. Katherine holds a PhD in Genetics from the University of Leicester.
Director of Research
Daniel currently leads efforts in applying data analytics, proteomics, and computational modelling to target identification and drug discovery. He has 16 years of experience in these areas and has worked at prestigious research institutions in the UK and Singapore. Additionally, he has extensive experience in developing ‘omics’ solutions within biotech start-up companies. Daniel holds a BSc in Biochemistry, an MSc in Bioinformatics, and a PhD in Computational Biochemistry.
Principal Data Scientist
As project manager for our bispecific programme, Robert brings 20 years of experience in biotechnology and molecular biology acquired through roles at GSK, CAT, Medimmune, F-Star & Genzyme. His research interests encompass protein engineering and biologic drug discovery with a particular focus on developing endo-lysosomal escape mechanisms for ADCs.
Antibody Program Manager
Director, Antibody Operations at Theraclone Sciences
President & CEO, Bionavigen
SrVP and Global Head Drug Development Unit ICON plc
Consultant Toxicologist
President of Health and Life Science Advisors
Partner at Sagittarius IP
Professor of Medicine
Professor of Functional Proteomics
Professor of Cancer Biology
